What is the current stock price of Perspective Therapeutics, Inc. (CATX)?

As of the latest market data, Perspective Therapeutics, Inc. (CATX) is trading at $4.47. The stock has seen a loss of -0.45% today.

Does Perspective Therapeutics, Inc. (CATX) pay a dividend?

Based on current data, Perspective Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Perspective Therapeutics, Inc.?

The current market capitalization of Perspective Therapeutics, Inc. (CATX) is approximately unavailable.

CATX

Perspective Therapeutics, Inc.·Healthcare

4.47

0.445%(−0.02)

Market Closed

4.54

1.566%(+0.07)

After Hours

Last Updated: — ET

52W L: $1.7552W H: $6.16

CATX NEWS

globenewswire.com

Apr 2

Perspective Therapeutics to Participate in Upcoming Investor Conferences

SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences:

globenewswire.com

Mar 17

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted as a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place from April 17 to 22, 2026 in San Diego, CA as detailed below. AACR has announced that it will release further details for clinical trial abstracts for the conference on April 17, 2026.

globenewswire.com

Mar 16

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

SEATTLE, March 16, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced full year results for the year ended December 31, 2025.

prnewswire.com

Feb 17

New Treatment Modalities Are Reaching Cancers That Resisted Everything Else

/PRNewswire/ -- Equity-Insider.com News Commentary - More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies

globenewswire.com

Feb 17

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its full year 2025 financial results and provide a business update on Monday, March 16, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.

defenseworld.net

Feb 7

Profusa (NASDAQ:PFSA) and Perspective Therapeutics (NASDAQ:CATX) Financial Contrast

Perspective Therapeutics (NASDAQ: CATX - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability. Insider and Institutional Ownership 54.7% of Perspective Therapeutics

Company Profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

Sector

Healthcare

Industry

Medical - Devices

Employees

138

IPO Date

2005-11-10

Beta

1.87

Websitewww.perspectivetherapeutics.com↗